Download Breast Cancer

Next-Gen Sequencing targeted therapeutics
Trial #
Diagnosis
EAY131
Any solid tumor and
lymphoma
Schema
NCI-MATCH is a phase II trial measuring
the therapeutic effectiveness of 22
different drugs or drug combinations for
pt with solid tumor or lymphoma that has
returned or gotten worse after standard
treatment, or among people with a rare
cancer for which there is no standard
treatment.
Drugs Provided
Status
various
Reopened
6/2016
Breast Cancer
Trial #
Diagnosis
Schema
Drugs Provided
Status
NSABP B51
N+ Pre-chemo  N- post
chemo
Chestwall and Regional Nodal XRT and
Post-Lumpectomy Regional Nodal XRT
None
Active
E2112
Postmenopausal Women
with Hormone ReceptorPositive Advanced
Cancer
Endocrine Therapy plus Entinostat/Placebo
ENTINOSTAT
***NEW***
CALL CANCER RESEARCH OFFICE 773-257-6110 WITH ANY QUESTIONS.
E1Z11
Breast cancer
A Cohort Study to Evaluate Genetic
Predictors of Aromatase Inhibitor
Musculoskeletal Symptoms
None
Breast Cancer (cT1-3 N1)
Axillary Lymph Node Dissection in Breast
Cancer Patients with Positive Sentinel
Lymph Node Disease After Neoadjuvant
Chemotherapy
None
Neoadjuvant Therapy in PostMeno
Patients Anastrazole vs Fulvestrant vs
Anastrazole + Fulvestrant
Fulvestrant
Active
Olaparib/Placebo
(BRCA testing
provided)
Active
(Local IRB)
A011202
A011106
NSABP B55
T2-T4c, Nany, M0, ER +
ER/PR +/- & HER2
negative adj or neoadj BRCA positive ;
Double-blind, Parallel group, Placebocontrolled Multi-centre Phase III Study to
Assess the Efficacy and Safety of Olaparib
Versus Placebo as Adjuvant Treatment in
Patients with Germline BRCA1/2 mutations
and High Risk HER2 Negative Primary Breast
Cancer Who Have Completed Definitive
Local Treatment and Neoadjuvant or
Adjuvant Chemotherapy
Active (only
Asian
ethnicity)
Active
Leiomyosarcoma
Trial #
Diagnosis
GOG-0277
High-Grade Uterine
Leiomyosarcoma
Schema
Gemcitabine, Docetaxel q 21days X 4
cycles
(if disease free after image confirmation
then) Doxorubicin q 21days X 4 cycles
VS Observation
Drugs Provided
Status
None
Active
CALL CANCER RESEARCH OFFICE 773-257-6110 WITH ANY QUESTIONS.
Colon and Rectal / Liver Cancer
Trial #
N1048
Diagnosis
Schema
Advance rectal ca stage ii and
iii
Neoadjuvant FOLFOX, with Selective
Use of Combined Modality
Chemoradiation versus Preoperative
Combined Modality Chemoradiation
Drugs Provided
Status
Active
None
Gastric Cancer
Trial #
Diagnosis
Schema
TAS-102-302
METASTATIC GASTRIC
CANCER REFRACTORY TO
STANDARD TREATMENTS
TAS-102 PLUS BEST SUPPORTIVE CARE (BSC)
Vs PLACEBO PLUS BSC
Drugs Provided
TAS-102
Status
**NEW**
Leukemia
Trial #
E1912
Treatment
Untreated CLL in younger
patients
Schema
A Randomized Phase III Study of Ibrutinib
(PCI-32765)-Based Therapy vs Standard
Fludarabine, Cyclophosphamide, and
Rituximab (FCR) Chemoimmunotherapy in
Untreated Younger Patients with Chronic
Lymphocytic Leukemia (CLL)
Drugs Provided
Status
Ibrutinib
***NEW***
CALL CANCER RESEARCH OFFICE 773-257-6110 WITH ANY QUESTIONS.
Newly Diagnosed BCR-ABLNegative B Lineage Acute
Lymphoblastic Leukemia in
Adults
E1910
A Phase III Randomized Trial of
Blinatumomab for Newly Diagnosed BCRABL-Negative B Lineage Acute
Lymphoblastic Leukemia in Adults
Blinatumomab & IV
Solution Stabilizer for
Blinatumomab (AMG
103)
***NEW***
Lung Cancer
Trial #
Diagnosis
Schema
Drugs Provided
Status
S1400
2nd line Squamous Cell Lung
Ca
Biomarker driven treatment
Multiple
ACTIVE
S1400I
2nd line Squamous Cell Lung
Ca
Nivolumab Plus Ipilimumab Versus
Nivolumab (no matching biomarker pts)
Nivolumab and
Ipilimumab
ACTIVE
S1400B
2nd line Squamous Cell Lung
Ca
GDC-0032 Versus Chemotherapy as
Second Line Therapy for Biomarker
Selected Patients
GDC-0032
ACTIVE
S1400C
2nd line Squamous Cell Lung
Ca
Palbociclib Versus Chemotherapy as
Second Line Therapy for Biomarker
Selected Patients
PALBOCICLIB
ACTIVE
S1400D
2nd line Squamous Cell Lung
Ca
AZD4547 Versus Chemotherapy as
Second Line Therapy for Biomarker
Selected Patients
AZD4547
IB – IIIA NSCLC
Genetic Testing in Screening Patients
with NSCLC that will be or has been
none
A151216
(ALCHEMIST)
ACTIVE
ACTIVE
CALL CANCER RESEARCH OFFICE 773-257-6110 WITH ANY QUESTIONS.
E4512
(ALCHEMIST)
A081105
(ALCHEMIST)
Adjuvant IB-IIIA NSCLC
Adjuvant IB-IIIA NSCLC
Adjuvant IB-IIIA NSCLC
EA5142
(ALCHEMIST)
B7391003
Metastatic Non-Squamous
NSCLC
removed surgically
Crizotinib/placebo in Treating Patients
with NSCLC That Has Been Removed
by Surgery and ALK Fusion Mutations
Double Blind Placebo Controlled Study of
Erlotinib or Placebo in Patients with
Completely Resected Epidermal Growth
Factor Receptor (EGFR) Mutant NSCLC
Crizotinib/placebo
Active
Erlotinib/Placebo
Active
Phase III Study of Nivolumab After
Surgical Resection and Adjuvant
Nivolumab vs
Chemotherapy in Non-Small Cell Lung Observation
Cancers
PF-06439535
Double-Blind
(avastin biosimilar)
PF-06439535 Plus PaclitaxelCarbo-taxol
Carboplatin Vs Bevacizumab Plus
(reimbursed)
Paclitaxel-Carboplatin
NEW***
**NEW**
(pending
)
Lymphoma
Trial #
Diagnosis
Schema
Drugs Provided
E1411
Untreated Mantle Cell
Lymphoma
RB- R vs RBV R vs RB LR vs RBV  LR
Bortezomib;
lenalidomide
Available
in July
Lenalidomide
Available
in July
E1412
Newly Diagnosed Diffuse
Large B Cell Lymphoma
Open label Lenalidomide R-CHOP
(R2CHOP) vs. RCHOP (Rituximab,
Cyclophosphamide, Doxorubicin,
Vincristine and Prednisone)
Status
CALL CANCER RESEARCH OFFICE 773-257-6110 WITH ANY QUESTIONS.
Myeloma
E3A06
E1A11
Smoldering Multiple
Myeloma
Lenalidomide vs Observation
Lenalidomide
Active
Newly Diagnosed
Symptomatic Multiple
Myeloma (ENDURANCE)
Phase III Trial of Bortezomib, LENalidomide
and Dexamethasone (VRd) Vs
Carfilzomib, Lenalidomide and
Dexamethasone (CRd) Followed by
Limited or Indefinite DURation
Lenalidomide MaintenANCE
Carfilzomib
Active
Prostate Cancer
Study #
Diagnosis
Schema
Drugs Provided
Status
SWOG 1216
New Metastatic Hormone
Sensitive Prostate ca
Androgen Dep therapy + TAK-700 or
Bicalumatide
TAK-700
Active
Castration Resistant Met
Prostate
Enzalutamide (NSC#766085) Versus
Enzalutamide, Abiraterone and
Prednisone
Enzalutamide
Active
A031201
CALL CANCER RESEARCH OFFICE 773-257-6110 WITH ANY QUESTIONS.